`
`UNITED STATES DISTRICT COURT
`SOUTHERN DISTRICT OF NEW YORK
`
`Kowa Company, Ltd.,
`Kowa Pharmaceuticals America, Inc., and
`Nissan Chemical Industries, Ltd.,
`
`Plaintiffs,
`
`v.
`
`Aurobindo Pharma Limited and
`Aurobindo Pharma USA Inc.,
`
`Defendants.
`
`Kowa Company, Ltd.,
`Kowa Pharmaceuticals America, Inc., and
`Nissan Chemical Industries, Ltd.,
`
`Plaintiffs,
`
`v.
`
`Amneal Pharmaceuticals, LLC,
`
`Defendants.
`
`Kowa Company, Ltd.,
`Kowa Pharmaceuticals America, Inc., and
`Nissan Chemical Industries, Ltd.,
`
`Plaintiffs,
`
`v.
`
`Mylan Inc. and Mylan Pharmaceuticals
`Inc.,
`
`Defendants.
`
`1
`
`Civil Action No. 14-CV-2497 (PAC)
`
`Civil Action No. 14-CV-2758 (PAC)
`
`Civil Action No. 14-CV-2647 (PAC)
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 2 of 10
`
`Kowa Company, Ltd.,
`Kowa Pharmaceuticals America, Inc., and
`Nissan Chemical Industries, Ltd.,
`
`Plaintiffs,
`
`v.
`
`Zydus Pharmaceuticals (USA) Inc., and
`Cadila Healthcare Ltd. (dba Zydus Cadila),
`
`Defendants.
`
`Kowa Company, Ltd.,
`Kowa Pharmaceuticals America, Inc., and
`Nissan Chemical Industries, Ltd.,
`
`Plaintiffs,
`
`v.
`
`Orient Pharma Co., Ltd.,
`
`Defendants.
`
`Kowa Company, Ltd.,
`Kowa Pharmaceuticals America, Inc., and
`Nissan Chemical Industries, Ltd.,
`
`Plaintiffs,
`
`v.
`
`Sawai USA, Inc., and
`Sawai Pharmaceutical Co., Ltd.,
`
`Defendants.
`
`Civil Action No. 14-CV-2760 (PAC)
`
`Civil Action No. 14-CV-2759 (PAC)
`
`Civil Action No. 14-CV-5575 (PAC)
`
`CIVIL CASE MANAGEMENT PLAN AND SCHEDULING ORDER
`
`This Civil Case Management Plan, submitted in accordance with Rule 26(f), Fed.
`R. Civ. P., is adopted as the Scheduling Order of this Court in accordance with Rule
`
`2
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 3 of 10
`
`16(f), Fed. R. Civ. P., and pursuant to the Initial Pretrial Conference in the above-
`captioned cases held on October 6, 2014.
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`All parties do not consent to conducting all further proceedings before a
`Magistrate Judge, including motions and trial. 28 U.S.C. § 636(c).
`
`This case is not to be tried to a jury.
`
`Parties may file amended pleadings or additional parties may be joined without
`leave of the Court on or before March 2, 2015.
`
`Initial disclosures pursuant to Rules 26(a)(1), Fed. R. Civ. P., shall be completed no
`later than October 20, 2014.
`
`All fact discovery shall be completed no later than October 5, 2015.
`
`The parties are to conduct discovery in accordance with the Federal Rules of
`Civil Procedure and the Local Rules of the Southern District of New York. The
`interim deadlines, as set forth in paragraphs 7-8 and 10-12, may be extended by
`the written consent of all parties without application to the Court, provided all
`fact discovery is completed by the date set forth in paragraph 5 above.
`
`Initial requests for production of documents to be served not later than
`November 20, 2014.
`
`Document production by all parties shall be substantially complete by May 1,
`2015.
`
`The parties shall propose a protective order to the Court on or before November
`20, 2014. Documents to be produced will be produced in accordance with the
`Protective Order adopted by the Court.
`
`10.
`
`Interrogatories to be served not later than September 4, 2015.
`
`a. The parties may commence serving Local Civil Rule 33.3(a) interrogatories on
`October 20, 2014. Defendants shall be permitted to serve up to 25 joint
`interrogatories on Plaintiffs. In addition, each Defendant shall be permitted
`to serve up to 10 individual interrogatories on Plaintiffs. Plaintiffs shall be
`permitted to serve up to 25 interrogatories on each Defendant (for clarity, e.g.,
`Mylan Inc. and Mylan Pharmaceuticals Inc. shall be treated collectively as a
`single Defendant).
`
`Depositions of fact witnesses to be completed by October 5, 2015. The parties
`shall meet and confer regarding logistics and scheduling of depositions of
`foreign witnesses, including locations of the depositions, by January 20, 2015.
`
`11.
`
`3
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 4 of 10
`
`12.
`
`13.
`
`Requests to Admit shall be served by no later than September 4, 2015.
`
`Expert Discovery:
`
`All expert discovery shall be completed no later than March 11, 2016.
`
`The parties’ opening expert reports shall be served by December 15, 2015.
`
`The parties’ responsive expert reports shall be served by January 29, 2016.
`
`The parties’ reply expert reports shall be served by February 15, 2016.
`
`Expert depositions shall conclude by March 11, 2016.
`
`14. Markman Proceedings
`
`a.
`
`A Markman (claim construction) hearing shall be held, if necessary, to
`determine the meaning of any terms for the claims of the patents-in-suit,
`as follows:
`
`(i) no later than February 27, 2015, each party shall exchange a list of potentially
`disputed claim terms;
`
`(ii) no later than March 13, 2015, each party shall identify and exchange its
`proposed construction of all of the potentially disputed claim terms;
`
`(iii) no later than March 27, 2015, the parties shall meet and confer to discuss and
`analyze the proposed construction of the claim terms, if the parties have a claim-
`term dispute;
`
`(iv) no later than April 6, 2015, the parties shall jointly file a Joint Disputed Claim
`Terms Chart pursuant to Local Patent Rule 11;
`
`(v) no later than May 6, 2015, Plaintiffs and Defendants shall file their opening
`claim construction brief
`(including any supporting intrinsic and extrinsic
`evidence);
`
`(vi) no later than June 8, 2015, Plaintiffs and Defendants shall file their responsive
`claim construction brief(s) (including any rebuttal evidence that could not have
`been raised in the opening submission);
`
`(vii) the claim construction hearing shall be held at a date and time to be
`scheduled by the Court, preferably before August 31, 2015.
`
`All motions and applications shall be governed by the Court’s Individual
`Practices, including pre-motion conference requirements.
`
`15.
`
`4
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 5 of 10
`
`16.
`
`The Final Pretrial Submission Date shall be April 25, 2016.
`
`By the Final Pretrial Submission Date, the parties shall submit a Joint Pretrial
`Order prepared in accordance with the Court’s Individual Practices and Rule
`26(a)(3), Fed. R. Civ. P. Any motions in limine (for which the pre-motion
`conference requirement is waived) shall be filed by the Final Pretrial Submission
`Date. Responsive briefs, if any, to said motions shall be filed 7 days after the Final
`Pretrial Submission Date.
`
`17.
`
`Counsel for the parties have conferred and their present best estimate of the
`length of trial is: 14 to 21 days.
`
`18.
`
`Summary of Civil Case Management Plan Scheduling Dates:
`
`Civil Case Management Plan Requirement
`Initial Disclosure pursuant to Rule 26(a)(1), Fed. R. Civ. P. to be
`served no later than:
`
`Dates:
`October 20, 2014
`
`Parties may file amended pleadings or additional parties may be
`joined without leave of the Court.
`
`March 2, 2015
`
`All fact discovery to be completed no later than:
`
` Fact Discovery - initial requests for production of
`documents to be served no later than:
` Deadline for the parties to meet and confer regarding logistics and
`scheduling of foreign witnesses for depositions, including
`locations of the depositions,
` Fact Discovery - Document Production: All parties shall
`substantially complete document production
`
`October 5, 2015
`
`November 20, 2014
`
`January 20, 2015
`
`May 1, 2015
`
` Fact Discovery - interrogatories (aside from those
`contemplated by Local Civil Rule 33.3(a)) to be served no
`later than:
`
`September 4, 2015
`
` Fact Discovery - requests to admit to be served no later
`than:
`
`September 4, 2015
`
` Fact Discovery - depositions of fact witnesses to be
`completed no later than:
`
`October 5, 2015
`
`5
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 6 of 10
`
`Markman Proceedings
`
` Markman - each party shall exchange a list of potentially
`disputed claim terms.
` Markman - each party shall identify and exchange its
`proposed construction of all of the potentially disputed
`claim terms
` Markman - the parties shall meet and confer to discuss and
`analyze the proposed construction of the claim terms, if the
`parties have a claim-term dispute.
`
` Markman - jointly file a Joint Disputed Claim Terms Chart
`pursuant to Local Patent Rule 11.
` Markman – Plaintiffs file opening claim construction brief,
`Defendants file opening claim construction brief.
` Markman – Plaintiffs and Defendants file responsive claim
`construction brief
` Markman – Claim Construction Hearing to preferably occur
`no later than:
`
`Counsel for Plaintiff and Counsel for Defendants to meet and
`confer separately to discuss settlement.
`
`Expert Discovery:
`All expert discovery, including depositions, to be completed no
`later than:
`
`February 27, 2015
`
`March 13, 2015
`
`March 27, 2015
`
`April 6, 2015
`
`May 6, 2015
`
`June 8, 2015
`
`August 31, 2015
`
`October 19, 2015
`
`March 11, 2016
`
` Expert Discovery – opening expert reports due
`
`December 15, 2015
`
` Expert Discovery – responsive expert reports due:
`
`January 29, 2016
`
` Expert Discovery – reply expert reports due:
`
`Deadline to file letter requesting permission to file summary
`judgment motions.
`
`Final Pretrial Submission Date
`
`Summary judgment hearing
`
`February 15, 2016
`
`March 11, 2016
`
`April 25, 2016
`
`TBD
`
`6
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 7 of 10
`
`Trial
`
`Defendants anticipate
`being trial-ready by
`August 2016.
`Plaintiffs propose that
`the trial date is to be
`scheduled by the Court
`after the Final Pretrial
`Submission date.
`
`This ORDER may not be modified or the dates herein extended, except
`by further Order of this Court for good cause shown. Any application to modify or
`extend shall be made in a written application in accordance with paragraph 1(E) of
`the Court’s Individual Practices and shall be made no less than two (2) days prior to
`the expiration of the date sought to be extended.
`
`The next conference is scheduled for Wednesday, January 14, 2015, at 4:45 p.m., in
`Courtroom 14-C.
`
`Dated: ____/____/20____
`New York, NY
`
`Paul A. Crotty
`United States District Judge
`
`________________________________
`
`7
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 8 of 10
`
`s/David G. Conlin
`Anthony J. Viola
`Andre K. Cizmarik
`Jennifer L. Dereka
`Zachary W. Silverman
`EDWARDS WILDMAN PALMER LLP
`750 Lexington Avenue
`New York, NY 10022
`(212) 308-4411
`aviola@edwardswildman.com
`acizmarik@edwardswildman.com
`jdereka@edwardswildman.com
`zsilverman@edwardswildman.com
`
`David G. Conlin (admitted pro hac vice)
`Kathleen B. Carr (admitted pro hac vice
`Adam P. Samansky
`EDWARDS WILDMAN PALMER LLP
`111 Huntington Avenue
`Boston, MA 02199
`dconlin@edwardswildman.com
`kcarr@edwardswildman.com
`asamansky@edwardswildman.com
`
`Attorneys for Plaintiffs
`Kowa Company, Ltd.
`Kowa Pharmaceuticals America, Inc. and
`Nissan Chemical Industries, Ltd.
`
`8
`
`s/
`Andrew J. Miller
`Constance S. Huttner
`BUDD LARNER, PC
`150 John F. Kennedy Parkway
`Short Hills, N J 07078-2703
`(973) 379-4800
`amiller@buddlarner.com
`chuttner@buddlarner.com
`
`Attorneys for Defendant,
`Amneal Pharmaceuticals, LLC
`
`s/Chandrika Vira
`H. Keeto Sabharwal
`Paul A. Ainsworth
`Chandrika Vira
`STERNE, KESSLER, GOLDSTEIN &
`FOX, PLLC
`1100 New York Avenue
`Washington, D.C. 20005
`(202) 772-8511
`keetos@skgf.com
`painsworth@skgf.com
`cvira@skgf.com
`
`Attorneys for Defendants
`Aurobindo Pharma Ltd. and
`Aurobindo Pharma USA Inc.
`
`s/Jakob B. Halpern
`Jakob B. Halpern
`SAIBER LLC
`One Gateway Center, Suite 1000
`Newark, NJ 07102
`(973) 622-3333
`jbh@saiber.com
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 9 of 10
`
`Of Counsel
`
`William A. Rakoczy
`Deanne M. Mazzochi
`Amy D. Brody
`Luke T. Shannon
`RAKOCZY MOLINO MAZZOCHI
`SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, IL 60654
`(312) 222-6301
`wrakoczy@rmmslegal.com
`dmazzochi@rmmslegal.com
`abrody@rmmslegal.com
`lshannon@rmmslegal.com
`
`Attorneys for Defendants
`Mylan Pharmaceuticals Inc. and Mylan Inc.
`
`s/Steven Gerber
`Steven Gerber
`Gonzalez Saggio & Harlan LLP
`292 Madison Avenue, Floor 19
`New York, NY 10017
`(212) 380-9560
`Steven_Gerber@gshllp.com
`
`Of Counsel:
`
`Don J. Mizerk
`Katherine E. Rohlf
`Husch Blackwell LLP
`120 S. Riverside Plaza, Suite 2200
`Chicago, IL 60606
`(312) 655-1500
`Don.Mizerk@huschblackwell.com
`Katherine.Rohlf@huschblackwell.com
`
`Attorneys for Defendant
`Orient Pharma Co., Ltd.
`
`9
`
`
`
`Case 1:14-cv-02758-PAC Document 30 Filed 10/10/14 Page 10 of 10
`
`s/
`Craig S. Kesch
`FLEMMING ZULACK
`WILLIAMSON ZAUDERER LLP
`One Liberty Plaza
`New York, NY 10006-1404
`(212) 412-9500
`ckesch@fzwz.com
`
`Chidambaram S. Iyer
`Michael Dzwonczyk
`Azy S. Kokabi
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave. NW
`Washington, DC 20037
`(202) 293-7060
`ciyer@sughrue.com
`mdzwonczyk@sughrue.com
`akokabi@sughrue.com
`
`Attorneys for Defendant
`Sawai USA Inc. and Sawai Pharmaceutical
`Co., Ltd.
`
`Steven J. Moore
`Vincent P. Rao II
`Kelley Drye & Warren LLP
`101 Park Avenue
`New York, NY 10178
`(212) 808-7800
`smoore@kelleydrye.com
`vrao@kelleydrye.com
`
`Attorneys for Defendants
`Zydus Pharmaceuticals (USA) Inc. and
`Cadila Healthcare Limited
`
`10
`
`